The American pharmaceutical companies Pfizer and Moderna raised by more than a quarter and a tenth, respectively, the price of their anticovid vaccines in the last supply contracts to the European Union, affirms this Sunday the newspaper “Financial Times”.
The terms of the contracts, signed this year through 2023 for a total of 2.1 billion doses, were renegotiated after clinical studies indicated that the mRNA-type vaccines of these two companies had better efficacy rates than the two companies. cheaper from Oxford / AstraZeneca and Johnson & Johnson, says the newspaper.
The price of a dose of the Pfizer preparation went from the current 15.50 euros to 19.50 euros, according to parts of the contract to which the FT has had access.
The price of a dose of Moderna went up to $ 25.50, of about 19 euros or 22.60 dollars fixed in the first supply agreement.
READ ALSO: Warning of prevention due to the passage of tropical waves
However, that amount It is less than about $ 28.5 that had been agreed previously, because the order was increased, explains the newspaper.
The newspaper notes that drug companies will make a lot of money as they countries increase their orders in order to administer third doses of the vaccine next winter.
In accordance with data from industry consultants, in 2022 it is expected that Pfizer, that shares profits with the German BioNTech, earns 56,000 million dollars from the sale of its vaccine, while Moderna would earn about 30,000 million.
AstraZeneca, which offers its preparation to cost price indefinitely to developing countries, would enter about 15,000 million dollars, affirms the FT.
According to the newspaper, the EU negotiated the most expensive new contracts with Pfizer and Moderna at a time when I was under pressure to increase supply, while regulators investigated the possible connection of drug preparationse J&J and AstraZeneca with unusual thrombi.